RyanDGentzlerMD(He/Him)

Oncology • Charlottesville, VA

Hematologic Oncology, Thoracic Cancer

Associate Professor of Medicine, University of Virginia Health

Join to view full profile

Dr. Gentzler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Gentzler's full profile

Already have an account?

Office
1240 Lee St
Charlottesville, VA 22908
Phone+1 434-924-9333

Fax+1 434-243-6086
Is this information wrong?

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2011 - 2014
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2008 - 2011
Lewis Katz School of Medicine at Temple UniversityClass of 2008
Davidson CollegeBS, 2000 - 2004

Certifications & Licensure

VA State Medical License 2014 - 2024
IL State Medical License 2011 - 2014
PA State Medical License 2008 - 2011
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC Start of enrollment: 2015 Mar 09
Completed
Phase 2
Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC Start of enrollment: 2015 Jun 04
Terminated
Phase 1, Phase 2
Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Start of enrollment: 2016 Aug 30
Active, not recruiting
Phase 1
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) Start of enrollment: 2016 Jul 22
Active, not recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer Start of enrollment: 2017 Nov 30
Completed
Phase 2
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Start of enrollment: 2019 Apr 16
Active, not recruiting
Phase 2
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer Start of enrollment: 2019 Feb 06
Recruiting
Phase 2, Phase 3
Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies Start of enrollment: 2022 Aug 25
Active, not recruiting
Not Applicable
Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread Start of enrollment: 2021 Apr 27
Completed
Phase 1
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations Start of enrollment: 2020 Jan 10
Active, not recruiting
Phase 3
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases Start of enrollment: 2024 Apr 01
Not yet recruiting
Phase 2
MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer Start of enrollment: 2023 Sep 26
Recruiting
Phase 2
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study Start of enrollment: 2023 Mar 14
Recruiting
Phase 3
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer Start of enrollment: 2022 Feb 07
Recruiting
Phase 3
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure Start of enrollment: 2021 Nov 17
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Impact of Opioid Use on Duration of Therapy and Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Elghawy, O., Novicoff, W., Young, P., Mock, J., Wynter, E., Gentzler, R., Martin, L., Hall, R.> ;Current Oncology. 2024 Jan 3
15 citations
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MA...
Gentzler, R. D., A Passaro, J Wang, Y Wang, S-H Lee, B Melosky, J-Y Shih, J Wang, K Azuma, O Juan-Vidal, M Cobo, E Felip, N Girard, A B Cortot, R Califano, F Cappuzzo,...> ;Annals of Oncology. 2024 Jan 1
1 citations
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399.
Ryan D Gentzler, Liza C Villaruz, John C Rhee, Bethany Horton, Joseph Mock, Michael Hanley, Kyeongmin Kim, Michelle A Rudek, Mitch A Phelps, Michael A Carducci, Richar...> ;The Oncologist. 2023 Nov 2
1 citations
Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175.
Ryan D Gentzler, Nisha A Mohindra, Shadia I Jalal, Karen L Reckamp, Richard D Hall, Nasser H Hanna, Young Kwang Chae, Marianna Koczywas, Irene B Helenowski, Jyoti D Patel> ;The Oncologist. 2024 Jan 5
1 citations
Relevance of the Updated Recursive Partitioning Analysis (U-RPA) Classification in the Contemporary Care of Patients with Brain Metastases.
Camilo E Fadul, Guneet Sarai, Joseph A Bovi, Alissa A Thomas, Wendy Novicoff, Roger Anderson, Ryan F Amidon, Samantha Schuetz, Rohit Singh, Amy Chang, Ryan D Gentzler,...> ;Cancers. 2023 Jun 20
A Brief Report of a Phase II trial Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell ...
Hirva Mamdani, Ryan Gentzler, Maitri Kalra, Susan Perkins, Sandra Althouse, Shadia I Jalal, Wei, C.> ;Clinical Lung Cancer. 2023 Jun 1
1 citations
Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibition in Combination With Chemotherapy: A Brief Report.
Lindsey B Shantzer, Sean C Dougherty, Fabian Bolte, John W Melson, Daniel R Reed, Alia C Lynch, Ryan D Gentzler, Wendy Novicoff, Richard D Hall> ;Clinical Lung Cancer. 2023 Mar 1
3 citations
Replicative Instability Drives Cancer Progression.
Benjamin B Morris, Jason P Smith, Qi Zhang, Zhijie Jiang, Oliver A Hampton, Michelle L Churchman, Susanne M Arnold, Dwight H Owen, Jhanelle E Gray, Patrick M Dillon, H...> ;Biomolecules. 2022 Oct 26
2 citations
A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: ...
Fatemeh Ardeshir-Larijani, Sandra K Althouse, Ticiana Leal, Lawrence Eric Feldman, Taher Abu Hejleh, Malini Patel, Ryan D Gentzler, Adam Ryan Miller, Nasser H Hanna> ;Clinical Lung Cancer. 2022 Nov 1
90 citations
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(...
Jonathan D Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, Katrina Z Kao, Ana Lako, Junko Tsuji, Yang Liu, Ryan C Brennick, Ryan D Gentzler, Carrie Lee, Joleen H...> ;The Lancet. Oncology. 2022 Feb 1
8 citations
Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy.
Fabian J Bolte, Nathan Wakefield, Lindsey Shantzer, Caroline Hubbard, Arun Krishnaraj, Wendy Novicoff, Ryan D Gentzler, Richard D Hall, Gentzler, R. D., Sloane McTavish> ;Frontiers in Oncology. 2022 Jan 1
1 citations
Bayesian Design for Identifying Cohort-Specific Optimal Dose Combinations Based on Multiple Endpoints: Application to a Phase I Trial in Non-Small Cell Lung Cancer
Bethany J. Horton, Nolan A. Wages, Ryan D. Gentzler> ;International Journal of Environmental Research and Public Health. 2021 Oct 30
1 citations
Erratum: A randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation for patients with metastatic colorectal cancer...
Arta M. Monjazeb, Anita Giobbie-Hurder, Ana Lako, Emily M. Thrash, Ryan C. Brennick, Katrina Z. Kao, Claire Manuszak, Ryan D. Gentzler, Anteneh Tesfaye, Salma K. Jabbo...> ;Clinical Cancer Research. 2021 Sep 1
118 citations
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial.
Gregory J. Riely, Joel W. Neal, D. Ross Camidge, Alexander I. Spira, Zofia Piotrowska, Daniel B. Costa, Anne S. Tsao, Jyoti D. Patel, Shirish M. Gadgeel, Lyudmila Bazh...> ;Cancer Discovery. 2021 Jul 1
36 citations
A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer.
Arta M Monjazeb, Anita Giobbie-Hurder, Ana Lako, Emily M Thrash, Ryan C Brennick, Katrina Z Kao, Claire Manuszak, Ryan D Gentzler, Anteneh Tesfaye, Salma K Jabbour, Ol...> ;Clinical Cancer Research. 2021 May 1
6 citations
MYBL2-Driven Transcriptional Programs Link Replication Stress and Error-prone DNA Repair With Genomic Instability in Lung Adenocarcinoma
Benjamin B. Morris, Nolan A. Wages, Patrick A. Grant, P. Todd Stukenberg, Ryan D. Gentzler, R. Hall, Wallace Akerley, Thomas K. Varghese, S. M. Arnold, Terence M. Will...> ;Frontiers in Oncology. 2021 Jan 8
76 citations
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC.
Mark M. Awad, Shirish M. Gadgeel, Hossein Borghaei, Amita Patnaik, James Chih-Hsin Yang, Steven Francis Powell, Ryan D. Gentzler, Renato G. Martins, James P. Stevenson...> ;Journal of Thoracic Oncology. 2021 Jan 1
17 citations
Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)
Erin M. Bertino, Ryan D. Gentzler, Sarah E. Clifford, Jill M. Kolesar, Alona Muzikansky, Eric B. Haura, Zofia Piotrowska, D. Ross Camidge, Thomas E. Stinchcombe, Chris...> ;Clinical Cancer Research. 2021 Mar 15
1 citations
Do Patients Regret Having Received Systemic Treatment for Advanced Non-Small Cell Lung Cancer: A Prospective Evaluation
Patricia J. Hollen, Richard J. Gralla, Ryan D. Gentzler, R. Hall, Bethany Coyne, Haiying Cheng, Balazs Halmos, Jane Gildersleeve, Claudia Calderon, Ivora Hinton, Geoff...> ;The Oncologist. 2021 Mar 1
78 citations
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier cancer ...
Greg Andrew Durm, Salma K. Jabbour, Sandra Althouse, Ziyue Liu, Ahad Ali Sadiq, Robin Zon, Shadia I. Jalal, Goetz H. Kloecker, Michael J. Williamson, Karen L. Reckamp,...> ;Cancer. 2020 Oct 1
14 citations
Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series
Puja C. Arora, Laura Talamo, Patrick M. Dillon, Ryan D. Gentzler, Trish A Millard, Michael Salerno, Craig L. Slingluff, Elizabeth M. Gaughan> ;Cardio-Oncology. 2020 Sep 23
5 citations
Intracranial disease control for EGFR -mutant and ALK -rearranged lung cancer with large volume or symptomatic brain metastases
Sunil W. Dutta, Marie L. Mack, Eric Aliotta, K.A. Ward, Donald A. Muller, James M. Larner, Camilo E. Fadul, R. Hall, Ryan D. Gentzler, Jason P. Sheehan> ;Journal of Neuro-Oncology. 2020 Sep 9
47 citations
Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study.
Matthew J. Shepard, Zhiyuan Xu, Joseph Donahue, Thomas Jose Eluvathingal Muttikkal, Diogo Cordeiro, Leslie Hansen, Nasser Mohammed, Ryan D. Gentzler, James M. Larner, ...> ;Journal of Neurosurgery. 2020 Sep 1
8 citations
Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy
Ryan D. Gentzler, David O. Riley, Linda W. Martin> ;Current Oncology Reports. 2020 Aug 15
5 citations
Genesis of Quality Measurements to Improve the Care Delivered to Patients With Brain Metastases.
Julio Silvestre, Tracey Gosse, Paul W. Read, Ryan D. Gentzler, Benjamin Purow, Ashok R. Asthagiri, Elizabeth Gaughan, Patrick M. Dillon, James M. Larner, Roger T. Ande...> ;JCO Oncology Practice. 2021 Mar 1
Join now to see all

Lectures

24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

OncLive® to Host State of the Science Summit™ on Advanced Non-Small Cell Lung CancerJuly 31st, 2018
UVA Health to Illuminate South Tower for Lung Cancer AwarenessNovember 19th, 2021